4,523 Shares of AbbVie Inc. $ABBV Bought by Livelsberger Financial Advisory

Livelsberger Financial Advisory bought a new stake in AbbVie Inc. (NYSE:ABBV) in the third quarter, Holdings Channel reports. The fund bought 4,523 shares of the company’s stock, valued at approximately $1,183,000. AbbVie makes up approximately 6.4% of Livelsberger Financial Advisory’s portfolio, making the stock its 3rd biggest position.

Several other large investors have also recently bought and sold shares of ABBV. Cornerstone Wealth LLC TN raised its position in shares of AbbVie by 10.3% during the 3rd quarter. Cornerstone Wealth LLC TN now owns 1,144 shares of the company’s stock worth $327,000 after buying an additional 107 shares in the last quarter. Fonville Wealth Management LLC lifted its stake in shares of AbbVie by 15.1% in the 3rd quarter. Fonville Wealth Management LLC now owns 1,752 shares of the company’s stock worth $458,000 after acquiring an additional 230 shares during the period. Morey & Quinn Wealth Partners LLC bought a new position in shares of AbbVie in the third quarter valued at approximately $212,000. Foundry Financial Group Inc. boosted its holdings in shares of AbbVie by 4.6% in the third quarter. Foundry Financial Group Inc. now owns 839 shares of the company’s stock valued at $219,000 after acquiring an additional 37 shares in the last quarter. Finally, Creative Capital Management Investments LLC boosted its holdings in shares of AbbVie by 7.4% in the third quarter. Creative Capital Management Investments LLC now owns 1,602 shares of the company’s stock valued at $419,000 after acquiring an additional 110 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Price Performance

ABBV stock opened at $289.85 on Friday. The firm has a market cap of $512.10 billion, a PE ratio of 81.88, a P/E/G ratio of 1.31 and a beta of 0.24. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $292.67. The firm has a 50 day simple moving average of $268.69 and a 200 day simple moving average of $236.86.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.97 earnings per share. As a group, sell-side analysts expect that AbbVie Inc. will post 13.92 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Scotiabank boosted their target price on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Barclays increased their price target on AbbVie from $300.00 to $325.00 and gave the company an “overweight” rating in a research note on Wednesday, October 21st. Weiss Ratings upgraded AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Finally, Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price target for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $279.86.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: QULIPTA delivered favorable Phase 3 results. AbbVie said its migraine-prevention treatment atogepant (QULIPTA) demonstrated superior efficacy and tolerability versus topiramate in the TEMPLE head-to-head study. The data could strengthen QULIPTA’s competitive position and support future growth. AbbVie’s QULIPTA Outperforms Topiramate in Phase 3 Migraine Prevention Study
• Positive Sentiment: Analysts expect a better-than-expected third quarter. The preview points to continued momentum from immunology drugs Skyrizi and Rinvoq, which are increasingly important as AbbVie replaces lost Humira revenue. A strong report and maintained or improved guidance could provide a near-term catalyst. AbbVie Q3 Preview
• Positive Sentiment: AbbVie filed for FDA review of etentamig. The multiple myeloma candidate is backed by a positive pivotal Phase 3 trial and could expand AbbVie’s oncology portfolio if approved. The monthly dosing schedule may also improve its commercial appeal. AbbVie Seeks FDA Approval for Etentamig
• Neutral Sentiment: Early-stage pipeline activity continues. An updated Phase 1 study of ABBV-7828 signals ongoing investment in new medicines, but the program remains preliminary and is unlikely to materially affect near-term earnings. AbbVie’s ABBV-7828 Trial
• Negative Sentiment: Patent-cliff concerns remain. Analysts continue to warn that Humira’s loss of exclusivity and future patent expirations could pressure revenue and earnings, placing greater importance on Skyrizi, Rinvoq, QULIPTA and the broader pipeline. AbbVie Still Strong Growth, but Patent Cliff Is Getting Closer

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.